FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977866745> ?p ?o ?g. }

• W2977866745 endingPage "v329" @default.
• W2977866745 startingPage "v329" @default.
• W2977866745 abstract "Abstract Background PD-1 inhibition (α-PD-1) can lead to deep, durable responses in mCRPC, but only in a minority of patients (pts). We previously reported 5 (18%) responders among 28 pts. No marker has been shown to universally predict response. Analysis of fecal microbiota from pts with epithelial cancers showed an association between elevated Akkermansia muciniphila (A. muc) levels and response to α-PD-1. To evaluate predictive markers, we treated an additional 30 pts obtaining tumor biopsies, blood, and fecal specimens collected for analysis. Methods 30 pts with mCRPC progressing on Enz received α-PD-1 pembrolizumab 200 mg IV every 3 weeks for 4 doses with continued Enz. Prior chemotherapy for mCRPC was prohibited. The primary endpoint was the proportion of pts with a prostate-specific antigen (PSA) decline ≥ 50%. The secondary endpoints were objective response, PSA progression-free survival (PFS), radiographic PFS, overall survival (OS) and correlative studies. Results Four of 30 (13%) achieved a PSA reduction ≥ 50%. Six of 24 (25%) pts with measurable disease responded radiographically. After median follow up of 17.4 months (mos), median PSA PFS was 5.57 mos (95%CI: 3.48-8.06). Median OS was 17.25 mos (95% CI: 7.71-17.68). Of 27 pts evaluable for radiographic PFS, 17 (63%) have progressed; median radiographic PFS was 5.26 mos (95% CI: 2.6-11.2). Eight pts had immune related adverse events. Single cell analysis revealed that immune cells represent an average 0.5% of cells in tumor biopsies. Single cell transcriptomic analysis prior to α-PD-1 in 12 pts revealed enrichment in a CD8+ exhausted T cell population (p  Conclusions Using single cell RNA sequencing, we reveal a T-cell signature associated with response, an observation not possible at the bulk transcriptome level. Responders had lower levels of fecal A. muc than non-responders, suggesting markers of α-PD-1 response in mCRPC may be different than in other cancer types. Clinical trial identification NCT02312557. Legal entity responsible for the study Julie N Graff. Funding Merck Sharp & Dohme. Disclosure J.N. Graff: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sharp & Dohme; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas/Pfizer. A.E. Moran: Research grant / Funding (institution): Merck Sharp & Dohme. J.J. Alumkal: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Janssen Biotech; Research grant / Funding (institution): Aragon Pharmaceuticals; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Zenith Epigenetics Ltd; Research grant / Funding (institution): Gilead Sciences Inc. R.C. Bergan: Leadership role, Licensing / Royalties, Full / Part-time employment: Third Coast Therapeutics. T.M. Beer: Research grant / Funding (institution): Alliance Foundation Trials; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Corcept Therapeutics; Research grant / Funding (institution): Endocyte Inc; Research grant / Funding (institution): Janssen Research & Development; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): OncoGenex; Research grant / Funding (institution): Sotio; Research grant / Funding (institution): Theraclone Sciences/OncoResponse; Advisory / Consultancy: AbbVie; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Clovis Oncology; Honoraria (self), Advisory / Consultancy: GlaxoSmithKline; Honoraria (self), Advisory / Consultancy: Janssen Biotech; Honoraria (self), Advisory / Consultancy: Janssen Japan; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Pfizer. All other authors have declared no conflicts of interest." @default.
• W2977866745 created "2019-10-10" @default.
• W2977866745 creator A5003380318 @default.
• W2977866745 creator A5007626753 @default.
• W2977866745 creator A5026868461 @default.
• W2977866745 creator A5031923765 @default.
• W2977866745 creator A5039922522 @default.
• W2977866745 creator A5048477205 @default.
• W2977866745 creator A5052694721 @default.
• W2977866745 creator A5056156623 @default.
• W2977866745 creator A5060420733 @default.
• W2977866745 creator A5083851328 @default.
• W2977866745 creator A5088872826 @default.
• W2977866745 date "2019-10-01" @default.
• W2977866745 modified "2023-09-28" @default.
• W2977866745 title "Phase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination of tumour-infiltrating immune cells and fecal microbiota" @default.
• W2977866745 doi "https://doi.org/10.1093/annonc/mdz248.005" @default.
• W2977866745 hasPublicationYear "2019" @default.
• W2977866745 type Work @default.
• W2977866745 sameAs 2977866745 @default.
• W2977866745 citedByCount "3" @default.
• W2977866745 countsByYear W29778667452020 @default.
• W2977866745 crossrefType "journal-article" @default.
• W2977866745 hasAuthorship W2977866745A5003380318 @default.
• W2977866745 hasAuthorship W2977866745A5007626753 @default.
• W2977866745 hasAuthorship W2977866745A5026868461 @default.
• W2977866745 hasAuthorship W2977866745A5031923765 @default.
• W2977866745 hasAuthorship W2977866745A5039922522 @default.
• W2977866745 hasAuthorship W2977866745A5048477205 @default.
• W2977866745 hasAuthorship W2977866745A5052694721 @default.
• W2977866745 hasAuthorship W2977866745A5056156623 @default.
• W2977866745 hasAuthorship W2977866745A5060420733 @default.
• W2977866745 hasAuthorship W2977866745A5083851328 @default.
• W2977866745 hasAuthorship W2977866745A5088872826 @default.
• W2977866745 hasBestOaLocation W29778667451 @default.
• W2977866745 hasConcept C121608353 @default.
• W2977866745 hasConcept C126322002 @default.
• W2977866745 hasConcept C143998085 @default.
• W2977866745 hasConcept C203014093 @default.
• W2977866745 hasConcept C2776551883 @default.
• W2977866745 hasConcept C2777701055 @default.
• W2977866745 hasConcept C2780057760 @default.
• W2977866745 hasConcept C2780192828 @default.
• W2977866745 hasConcept C502942594 @default.
• W2977866745 hasConcept C61367390 @default.
• W2977866745 hasConcept C71924100 @default.
• W2977866745 hasConcept C8891405 @default.
• W2977866745 hasConceptScore W2977866745C121608353 @default.
• W2977866745 hasConceptScore W2977866745C126322002 @default.
• W2977866745 hasConceptScore W2977866745C143998085 @default.
• W2977866745 hasConceptScore W2977866745C203014093 @default.
• W2977866745 hasConceptScore W2977866745C2776551883 @default.
• W2977866745 hasConceptScore W2977866745C2777701055 @default.
• W2977866745 hasConceptScore W2977866745C2780057760 @default.
• W2977866745 hasConceptScore W2977866745C2780192828 @default.
• W2977866745 hasConceptScore W2977866745C502942594 @default.
• W2977866745 hasConceptScore W2977866745C61367390 @default.
• W2977866745 hasConceptScore W2977866745C71924100 @default.
• W2977866745 hasConceptScore W2977866745C8891405 @default.
• W2977866745 hasLocation W29778667451 @default.
• W2977866745 hasOpenAccess W2977866745 @default.
• W2977866745 hasPrimaryLocation W29778667451 @default.
• W2977866745 hasRelatedWork W2831103683 @default.
• W2977866745 hasRelatedWork W2904709685 @default.
• W2977866745 hasRelatedWork W2927728931 @default.
• W2977866745 hasRelatedWork W2996229517 @default.
• W2977866745 hasRelatedWork W3016632711 @default.
• W2977866745 hasRelatedWork W3164969052 @default.
• W2977866745 hasRelatedWork W3197069188 @default.
• W2977866745 hasRelatedWork W4361849260 @default.
• W2977866745 hasRelatedWork W4361849348 @default.
• W2977866745 hasRelatedWork W4379983849 @default.
• W2977866745 hasVolume "30" @default.
• W2977866745 isParatext "false" @default.
• W2977866745 isRetracted "false" @default.
• W2977866745 magId "2977866745" @default.
• W2977866745 workType "article" @default.